These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21390183)

  • 1. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.
    Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ
    Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile salts differentially sensitize esophageal squamous cells to CD95 (Fas/Apo-1 receptor) mediated apoptosis.
    Naran S; Abrams P; de Oliveira PQ; Hughes SJ
    J Surg Res; 2011 Dec; 171(2):504-9. PubMed ID: 20934723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.
    Hughes SJ; Nambu Y; Soldes OS; Hamstra D; Rehemtulla A; Iannettoni MD; Orringer MB; Beer DG
    Cancer Res; 1997 Dec; 57(24):5571-8. PubMed ID: 9407969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells.
    Reinehr R; Sommerfeld A; Häussinger D
    Gastroenterology; 2008 May; 134(5):1494-506. PubMed ID: 18471522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.
    Lang I; Fick A; Schäfer V; Giner T; Siegmund D; Wajant H
    J Biol Chem; 2012 Jul; 287(28):24026-42. PubMed ID: 22645131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells.
    Bourkoula K; Englert C; Giaisi M; Köhler R; Krammer PH; Li-Weber M
    Int J Cancer; 2014 Jan; 134(2):291-300. PubMed ID: 23832418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells.
    Fulda S; Strauss G; Meyer E; Debatin KM
    Blood; 2000 Jan; 95(1):301-8. PubMed ID: 10607716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR.
    Pinti M; Nasi M; Moretti L; Mussini C; Petrusca D; Esposito R; Cossarizza A
    Ann N Y Acad Sci; 2000; 926():46-51. PubMed ID: 11193040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma.
    Mahidhara RS; Queiroz De Oliveira PE; Kohout J; Beer DG; Lin J; Watkins SC; Robbins PD; Hughes SJ
    J Surg Res; 2005 Feb; 123(2):302-11. PubMed ID: 15680394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD95 ligand expression as a mechanism of immune escape in breast cancer.
    Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
    Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD95 Stimulation with CD95L and DISC Analysis.
    Le Gallo M; Legembre P
    Methods Mol Biol; 2017; 1557():11-18. PubMed ID: 28078578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
    Li JH; Kluger MS; Madge LA; Zheng L; Bothwell AL; Pober JS
    Am J Pathol; 2002 Oct; 161(4):1485-95. PubMed ID: 12368221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
    Pohl U; Wagenknecht B; Naumann U; Weller M
    Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
    Quijano-Rubio C; Silginer M; Weller M
    J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
    Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
    Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
    Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
    Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection.
    Cossarizza A; Stent G; Mussini C; Paganelli R; Borghi V; Nuzzo C; Pinti M; Pedrazzi J; Benatti F; Esposito R; Røsok B; Nagata S; Vella S; Franceschi C; De Rienzo B
    AIDS; 2000 Mar; 14(4):345-55. PubMed ID: 10770536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD95/Fas ligand induced toxicity.
    Haluck-Kangas A; Peter ME
    Biochem Soc Trans; 2023 Feb; 51(1):21-29. PubMed ID: 36629505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95.
    Re D; Hofmann A; Wolf J; Diehl V; Staratschek-Jox A
    Exp Hematol; 2000 Jan; 28(1):31-5. PubMed ID: 10658674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.
    Moers C; Warskulat U; Müschen M; Even J; Niederacher D; Josien R; Koldovsky U; Beckmann MW; Häussinger D
    Int J Cancer; 1999 Feb; 80(4):564-72. PubMed ID: 9935158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.